- Global Pharma News & Resources

Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering

NEW YORK and MELBOURNE, Australia, Sept. 30, 2019 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) ("Benitec" or the "Company") announces it has entered into a securities purchase agreement ("SPA") with certain sophisticated and professional investors in the United States ("Investors") to issue 2,800,000 American Depositary Shares ("ADSs"), with each ADS representing 20 fully paid ordinary shares, at a purchase price of US$0.70 per ADS, in a registered direct offering. The Investors will also be issued warrants to purchase up to 412,863 ADSs in aggregate, at a purchase price per warrant equal to US$0.6999 per ADS to be issued on exercise of the warrant ("Pre-Funded Warrants"). The Pre-Funded Warrants may be exercised at any time from issue, in whole or in part, at an exercise price of US$0.0001 per ADS issued on exercise (subject to certain adjustments), provided that the beneficial ownership of the relevant Investor in the total number of ADSs on issue may not exceed 9.99%. The Pre-Funded Warrants do not expire.

The issue of the ADSs and Pre-Funded Warrants will raise gross proceeds of approximately US$2.25 million (approximately A$3.33 million)1 exclusive of costs. The ADSs (and the underlying ordinary shares) and Pre-Funded Warrants will be issued without shareholder approval under the Company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A.

In a concurrent private placement, the Company has also agreed to issue additional warrants to the Investors to purchase up to a further 3,212,864 ADSs in aggregate ("Purchase Warrants"). The issue of the Purchase Warrants is subject to shareholder approval. If approved by shareholders, the Purchase Warrants will be issued for nil consideration, will have an exercise price of US$0.70 per ADS and will expire in five years from the date of issuance.

Benitec intends to use the net proceeds from this offering for product development and general corporate purposes. The ADSs will be listed on the Nasdaq Capital Market under the symbol BNTC.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American: LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.

The registered direct offering is expected to close on or about September 30, 2019 (New York time), subject to the satisfaction of customary closing conditions. Settlement and issuance of the ADSs (and underlying ordinary shares) and Pre-Funded Warrants is expected to take place on the same day.

The ADSs to be issued pursuant to the SPA represent 56,000,000 fully paid ordinary shares in the Company. The maximum number of fully paid ordinary shares (to be represented by ADSs) which may be issued on exercise of the Pre-Funded warrants is 8,257,260. The issue of the ADSs and Pre-Funded Warrants will fully utilise the Company's existing placement capacity under ASX Listing Rule 7.1. The remaining ADSs will be issued under the Company's placement capacity under ASX Listing Rule 7.1A. The ordinary shares issued will rank equally with other existing ordinary shares on issue.

A shelf registration statement relating to the ADSs and Pre-Funded Warrants offered in the registered direct offering described above was filed with the Securities and Exchange Commission ("SEC") on June 1, 2017, and became effective on July 5, 2017. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the registered direct offering will be filed with the SEC. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website at or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172 or by email at

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Benitec Biopharma Limited
Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company focused on the development of novel genetic medicines. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Based in Melbourne, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including oculopharyngeal muscular dystrophy (OPMD), and chronic hepatitis B.

Safe Harbor Statement:
This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in this ASX/Nasdaq announcement are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialise its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Investor Relations
M Group Strategic Communications
Jay Morakis
Managing Director Tel: +1 646 859 5951

1 Using an AUD/USD exchange rate of AUD 0.6761/USD.

View original content:

SOURCE Benitec Biopharma Limited

Editor Details

Last Updated: 30-Sep-2019